Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week Low - Time to Sell?

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report)'s stock price hit a new 52-week low on Tuesday . The company traded as low as $5.78 and last traded at $5.80, with a volume of 5762476 shares trading hands. The stock had previously closed at $6.05.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on FOLD shares. Wells Fargo & Company cut their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research report on Thursday, February 20th. UBS Group increased their target price on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Wall Street Zen downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. Finally, The Goldman Sachs Group dropped their price target on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $16.22.

Amicus Therapeutics Stock Down 4.1%

The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of -32.22, a P/E/G ratio of 1.51 and a beta of 0.54. The stock's fifty day moving average price is $6.46 and its 200-day moving average price is $8.28.

Institutional Investors Weigh In On Amicus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Choreo LLC acquired a new position in shares of Amicus Therapeutics during the 4th quarter worth approximately $103,000. Stephens Inc. AR acquired a new position in Amicus Therapeutics during the fourth quarter worth $101,000. State of New Jersey Common Pension Fund D increased its holdings in Amicus Therapeutics by 29.5% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 220,500 shares of the biopharmaceutical company's stock worth $2,077,000 after buying an additional 50,236 shares during the last quarter. Peregrine Capital Management LLC increased its holdings in Amicus Therapeutics by 18.2% during the fourth quarter. Peregrine Capital Management LLC now owns 880,517 shares of the biopharmaceutical company's stock worth $8,294,000 after buying an additional 135,716 shares during the last quarter. Finally, Rice Hall James & Associates LLC increased its stake in shares of Amicus Therapeutics by 41.0% during the 4th quarter. Rice Hall James & Associates LLC now owns 1,371,080 shares of the biopharmaceutical company's stock worth $12,916,000 after purchasing an additional 398,942 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.